Curated News
By: NewsRamp Editorial Staff
November 16, 2026

Quantum BioPharma Boosts Liquidity to $12.22M, Advances Lucid-MS Phase 2 Trial

TLDR

  • Quantum BioPharma boosted liquidity to $12.22 million, cut operating expenses 24%, and advanced its Lucid-MS Phase 2 trial, strengthening its competitive position.
  • Quantum BioPharma reduced operating cash use 21% and repaid $1 million in debt, while initiating its Phase 2 Lucid-MS trial with Thermo Fisher Scientific.
  • Quantum BioPharma's progress on Lucid-MS for progressive multiple sclerosis could lead to a treatment that prevents myelin degradation, improving patients' lives.
  • Quantum BioPharma holds $8.66 million in digital assets and invented UNBUZZD, an OTC product with a 7% royalty stream until $250 million is reached.

Impact - Why it Matters

Quantum BioPharma’s improved financial position—marked by a 91% increase in shareholders’ equity and a 24% reduction in operating expenses—provides the company with a stronger runway to advance its lead asset, Lucid-MS, into Phase 2 trials for progressive multiple sclerosis, a condition with limited treatment options. The partnership with Thermo Fisher Scientific’s clinical research business lends credibility and operational expertise to the trial, potentially accelerating timelines. For investors, the growth in digital asset holdings and debt reduction signal prudent capital management, while the royalty stream from UNBUZZD™ offers a unique revenue opportunity. If Lucid-MS succeeds, it could represent a novel approach to treating MS by targeting myelin degradation, addressing a significant unmet need and potentially transforming the treatment landscape for neurodegenerative diseases.

Summary

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, showcasing a strengthened balance sheet and progress in its clinical pipeline. The company’s cash and cash equivalents stood at approximately $3.56 million, while digital assets reached $8.66 million, bringing combined holdings to $12.22 million—a substantial increase from $4.12 million at year-end 2025, excluding restricted digital assets. Shareholders’ equity jumped 91% to $9.77 million, and working capital improved dramatically to $5.47 million from $420,000. Operating expenses for the quarter fell 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million. The company also reduced its operating cash use by 21% in the first nine months of 2026 and decreased notes payable to $300,000 after repaying $1 million in debt. Management expressed confidence that current cash and digital asset holdings are sufficient to fund planned operations over the next 12 months.

In a significant post-quarter development, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. This agreement follows the U.S. Food and Drug Administration’s clearance of the company’s Investigational New Drug application in August 2026. Lucid-MS, developed by Quantum’s wholly owned subsidiary Lucid Psycheceuticals Inc., is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Additionally, Quantum invented UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake and royalties of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. For more details, view the full press release at https://ibn.fm/GJ1ER.

Source Statement

This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Quantum BioPharma Boosts Liquidity to $12.22M, Advances Lucid-MS Phase 2 Trial

Blockchain registration record for this content